Development and responses of brain metastases during treatment with trastuzumab emtansine (T-DM1) for HER2 positive advanced breast cancer: A single institution experience
Author:
Affiliation:
1. The Royal Marsden NHS Foundation Trust; London and Surrey UK
Publisher
Hindawi Limited
Subject
Oncology,Surgery,Internal Medicine
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/tbj.12906/fullpdf
Reference24 articles.
1. Trastuzumab emtansine for HER2-positive advanced breast cancer;Verma;N Engl J Med,2012
2. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial;Krop;Lancet Oncol,2014
3. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma;Bendell;Cancer,2003
4. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA;Krop;Ann Oncol,2015
5. Preclinical efficacy of ado-trastuzumab emtansine in the brain microenvironment;Askoxylakis;J Natl Cancer Inst,2015
Cited by 20 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. A clinical systematic literature review of treatments among patients with advanced and/or metastatic human epidermal growth factor receptor 2 positive breast cancer;Journal of Comparative Effectiveness Research;2024-06
2. Development, efficacy and side effects of antibody‑drug conjugates for cancer therapy (Review);Molecular and Clinical Oncology;2023-05-04
3. Systemic Therapy for Patients with HER2-Positive Breast Cancer and Brain Metastases: A Systematic Review and Meta-Analysis;Cancers;2022-11-15
4. Treatment of Brain Metastases: The Synergy of Radiotherapy and Immune Checkpoint Inhibitors;Biomedicines;2022-09-07
5. Drug Delivery to Primary and Metastatic Brain Tumors: Challenges and Opportunities;Drug Delivery to the Brain;2022
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3